Source: Journal of Biotechnology and Biomaterials. Conference titles: Global Congress on Biotechnology. Unidade: FCF
ABNT
COSTA, Iris Munhoz et al. Engineered erwinase with possible fewer adverse effects for treatment of acute lymphoblastic leukemia. Journal of Biotechnology and Biomaterials. Sunnyvale: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://doi.org/10.4172/2155-952X-C2-116. Acesso em: 26 abr. 2026. , 2019APA
Costa, I. M., Moura, D. C., Pessoa Junior, A., & Monteiro, G. (2019). Engineered erwinase with possible fewer adverse effects for treatment of acute lymphoblastic leukemia. Journal of Biotechnology and Biomaterials. Sunnyvale: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.4172/2155-952X-C2-116NLM
Costa IM, Moura DC, Pessoa Junior A, Monteiro G. Engineered erwinase with possible fewer adverse effects for treatment of acute lymphoblastic leukemia [Internet]. Journal of Biotechnology and Biomaterials. 2019 ; 9 57.[citado 2026 abr. 26 ] Available from: https://doi.org/10.4172/2155-952X-C2-116Vancouver
Costa IM, Moura DC, Pessoa Junior A, Monteiro G. Engineered erwinase with possible fewer adverse effects for treatment of acute lymphoblastic leukemia [Internet]. Journal of Biotechnology and Biomaterials. 2019 ; 9 57.[citado 2026 abr. 26 ] Available from: https://doi.org/10.4172/2155-952X-C2-116
